<ul>
<li>记录了 2025 年第四季度收入为 1286 亿韩元，2025 财年收入为 4557 亿韩元</li>
<li>通过持续的运营表现和强劲的客户需求保持了增长势头</li>
<li>通过扩大制造准备和运营规模，巩固了长期增长的基础</li>
</ul>
<p>, /PRNewswire/ -- 三星生物制剂（KRX: 207940.KS），一家领先的合同开发和制造组织（CDMO），公布了 2025 年第四季度和财年的财务业绩。</p>
<p>&#34;在 2025 年，尽管全球环境高度不确定，三星生物制剂依然交出了稳定且具有韧性的业绩，这得益于严格的执行和强劲的需求，&#34;三星生物制剂总裁兼首席执行官 John Rim 表示。&#34;我们现有工厂的持续运营和第四工厂的成功增产，支持了全年客户项目的可靠交付。展望未来，我们计划扩展制造能力，包括增加美国制造基地，将进一步增强供应链的韧性和对全球客户需求的响应能力。我们将继续专注于增强制造准备、运营一致性和质量卓越，以支持作为全球生物制药行业可信赖合作伙伴的可持续长期增长。&#34;</p>
<p><strong>财务亮点</strong></p>
<p>在 2025 年第四季度，三星生物制剂报告收入为 1286 亿韩元，营业利润达到 528 亿韩元。该业绩主要得益于第一至第三工厂的全面利用，以及在 2025 年第三季度也实现全面利用的第四工厂。</p>
<p>在 2025 财年，三星生物制剂实现收入 4557 亿韩元，反映出公司在制造网络中稳定的运营和扩展的项目执行。</p>
<p>[CDMO 业务合并收益，剥离后基础，单位：亿韩元]</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q4'25</td>
<td>Q4'24</td>
<td>同比变化</td>
<td>FY25</td>
<td>FY24</td>
<td>同比变化</td>
</tr>
<tr>
<td>收入</td>
<td>1,285.7</td>
<td>950.3</td>
<td>+335.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(+35.3%)</td>
<td>4,557.0</td>
<td>3,497.1</td>
<td>+1,059.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(+30.3%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>营业利润</td>
<td>528.3</td>
<td>314.7</td>
<td>+213.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(67.9%)</td>
<td>2,069.2</td>
<td>1,321.4</td>
<td>+747.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(+56.6%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EBITDA</td>
<td>623.5</td>
<td>388.7</td>
<td>+234.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(+60.4%)</td>
<td>2,439.1</td>
<td>1,622.2</td>
<td>+816.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(+50.4%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p><strong>业务更新及 2026 年展望</strong></p>
<p>三星生物制剂通过与全球制药公司建立长期合作关系，继续扩展其全球 CDMO 业务。公司在 2025 年第四季度与一家欧洲制药公司签署了价值 1.1 万亿韩元的制造协议，使累计合同价值超过 210 亿美元。累计监管批准达到 420 项，反映出公司持续关注质量、合规性和在全球市场上的一致监管执行。</p>
<p>公司通过股权剥离重申了其作为纯粹 CDMO 的战略方向，并继续推进加强其全球制造平台的举措。第一至第四工厂的运营保持稳定，提供了坚实的运营基础，而第五工厂将在 2026 年开始贡献收入。基于这一展望，排除计划收购美国工厂的潜在贡献，公司预计 2026 年年收入增长 15-20%。</p>
<p>三星生物制剂推进了关键基础设施和产能投资，以支持未来需求。2025 年 12 月，公司宣布计划收购位于马里兰州罗克维尔的美国制造设施，以进一步支持供应韧性和靠近客户。该地点包括两个 CGMP 制造工厂，合计 60 kL 的药物物质产能，支持中到大规模项目。交易预计将在 2026 年第一季度完成，公司计划进行额外投资以增加产能和升级该地点的技术。</p>
<p>公司还为生物园区 III 获得了土地，为未来扩展奠定基础，以支持下一代技术和多样化的客户需求。生物园区 III 预计将支持在先进的结合技术、细胞和基因疗法以及抗体疫苗方面的扩展能力。</p>
<p>在其优化的制造框架 ExellenS™下，三星生物制剂继续投资于运营系统、数字能力和制造基础设施，以增强其设施的准备和执行能力。公司正在扩展其药物产品能力，包括为完全自动化的预填充注射器药物产品线做准备，预计将在 2027 年达到 CGMP 标准。</p>
<p>三星生物制剂继续推进其环境、社会和治理（ESG）倡议。公司在碳披露项目（CDP）中获得了水安全 “A” 评级，并继续作为可持续市场倡议的冠军，支持朝着更可持续的医疗制造实践的协作行动。通过加强与供应商的互动，并在其运营和价值链中整合 ESG 考量，三星生物制剂旨在支持长期的环境管理，同时保持可靠和负责任的制造运营。</p>
<p>有关业绩和财务的更多详细信息，请参阅财报。</p>
<p><strong>关于三星生物制剂有限公司</strong></p>
<p>三星生物制剂（KRX: 207940.KS）是一家领先的合同开发和制造组织（CDMO），提供从后期发现到商业制造的端到端综合服务。</p>
<p>三星生物制剂在生物园区 I 和 II 的合计生物制造能力为 785,000 升，并计划在 2026 年第一季度末完成对美国马里兰州罗克维尔一家制造设施的收购，增加 60,000 升的产能。三星生物制剂利用尖端技术和专业知识推进多种治疗方式，包括多特异性抗体、融合蛋白、抗体药物偶联物和 mRNA 治疗。</p>
<p>通过在其制造网络中实施 ExellenS™框架，采用标准化设计、统一流程和先进数字化，三星生物制剂确保工厂的等效性和制造连续性的速度。</p>
<p>三星生物制剂的全球制造和商业网络覆盖韩国、美国和日本。三星生物制剂美国公司支持位于美国和欧洲的客户，而其东京销售办公室服务于亚太地区。三星生物制剂持续投资于新能力，以最大化运营和质量卓越，确保客户的灵活性和敏捷性。公司致力于按时、完整地交付安全、高质量的生物药品，并做出可持续的商业决策，以改善社会和全球健康。</p>
<p>欲了解更多信息，请访问 https://samsungbiologics.com/。</p>
<p><strong>媒体联系人</strong> Claire Kim, 高级总监 [email protected]</p>
<p>Becky Lee, 总监 [email protected]</p>
<p>来源 三星生物制剂</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTIxJk5ld3NJdGVtSWQ9Q042Nzc1OSZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjEwMjIwUFJfTkVXU19VU1BSX19fX19DTjY3NzU5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTIxJk5ld3NJdGVtSWQ9Q042Nzc1OSZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjEwMjIwUFJfTkVXU19VU1BSX19fX19DTjY3NzU5"/></p>

<p>三星生物制剂公布了 2025 财年第四季度和全年财务业绩，第四季度收入为 1286 亿韩元，全年收入为 4557 亿韩元，反映出强劲的运营表现和客户需求。公司计划扩大其制造能力，包括在美国新建设施，并预计 2026 年收入增长 15-20%。三星生物制剂继续专注于质量和合规性，获得了重要合同并推进 ESG 倡议。公司旨在提升其制造基础设施和能力，以满足未来的需求</p>

<ul>
<li>Recorded Q4'25 revenue of KRW 1,286 billion and FY'25 revenue of KRW 4,557 billion</li>
<li>Maintained momentum through consistent operational performance and robust client demand</li>
<li>Strengthened foundation for long-term growth through expanded manufacturing readiness and operational scale</li>
</ul>
<div class="lb-trans"><ul>
<li>记录了 2025 年第四季度收入为 1286 亿韩元，2025 财年收入为 4557 亿韩元</li>
<li>通过持续的运营表现和强劲的客户需求保持了增长势头</li>
<li>通过扩大制造准备和运营规模，巩固了长期增长的基础</li>
</ul>
</div><p>, /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the fourth quarter and fiscal year 2025.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- 三星生物制剂（KRX: 207940.KS），一家领先的合同开发和制造组织（CDMO），公布了 2025 年第四季度和财年的财务业绩。</p>
</div><p>&#34;In 2025, Samsung Biologics delivered stable and resilient performance despite a highly uncertain global environment, supported by disciplined execution and strong demand,&#34; said John Rim, President and CEO of Samsung Biologics. &#34;Consistent operations across our existing plants and successful ramp-up of Plant 4 supported reliable delivery for client programs throughout the year. As we move forward, our planned expansion of manufacturing capabilities, including the addition of a U.S. manufacturing footprint, will further enhance supply chain resilience and responsiveness to global client needs. We remain focused on strengthening manufacturing readiness, operational consistency, and quality excellence to support sustainable long-term growth as a trusted partner to the global biopharmaceutical industry.&#34;</p>
<div class="lb-trans"><p>&#34;在 2025 年，尽管全球环境高度不确定，三星生物制剂依然交出了稳定且具有韧性的业绩，这得益于严格的执行和强劲的需求，&#34;三星生物制剂总裁兼首席执行官 John Rim 表示。&#34;我们现有工厂的持续运营和第四工厂的成功增产，支持了全年客户项目的可靠交付。展望未来，我们计划扩展制造能力，包括增加美国制造基地，将进一步增强供应链的韧性和对全球客户需求的响应能力。我们将继续专注于增强制造准备、运营一致性和质量卓越，以支持作为全球生物制药行业可信赖合作伙伴的可持续长期增长。&#34;</p>
</div><p><strong>Financial Highlights</strong></p>
<div class="lb-trans"><p><strong>财务亮点</strong></p>
</div><p>In the fourth quarter of 2025, Samsung Biologics reported revenue of KRW 1,286 billion, while operating profit reached KRW 528 billion. The performance was mainly driven by full utilization across Plants 1 through 3, together with Plant 4, which also reached full utilization in the third quarter of 2025.</p>
<div class="lb-trans"><p>在 2025 年第四季度，三星生物制剂报告收入为 1286 亿韩元，营业利润达到 528 亿韩元。该业绩主要得益于第一至第三工厂的全面利用，以及在 2025 年第三季度也实现全面利用的第四工厂。</p>
</div><p>For the full fiscal year 2025, Samsung Biologics achieved revenue of KRW 4,557 billion, reflecting stable operations and expanded project execution across the company's manufacturing network.</p>
<div class="lb-trans"><p>在 2025 财年，三星生物制剂实现收入 4557 亿韩元，反映出公司在制造网络中稳定的运营和扩展的项目执行。</p>
</div><p>[Consolidated earnings for CDMO business, post spin-off basis, KRW billion]</p>
<div class="lb-trans"><p>[CDMO 业务合并收益，剥离后基础，单位：亿韩元]</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q4'25</td>
<td>Q4'24</td>
<td>YoY Change</td>
<td>FY25</td>
<td>FY24</td>
<td>YoY Change</td>
</tr>
<tr>
<td>Revenue</td>
<td>1,285.7</td>
<td>950.3</td>
<td>+335.4<br/>(+35.3%)</td>
<td>4,557.0</td>
<td>3,497.1</td>
<td>+1,059.9<br/>(+30.3%)</td>
</tr>
<tr>
<td>Operating Profit</td>
<td>528.3</td>
<td>314.7</td>
<td>+213.6<br/>(67.9%)</td>
<td>2,069.2</td>
<td>1,321.4</td>
<td>+747.8<br/>(+56.6%)</td>
</tr>
<tr>
<td>EBITDA</td>
<td>623.5</td>
<td>388.7</td>
<td>+234.8<br/>(+60.4%)</td>
<td>2,439.1</td>
<td>1,622.2</td>
<td>+816.9<br/>(+50.4%)</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q4'25</td>
<td>Q4'24</td>
<td>同比变化</td>
<td>FY25</td>
<td>FY24</td>
<td>同比变化</td>
</tr>
<tr>
<td>收入</td>
<td>1,285.7</td>
<td>950.3</td>
<td>+335.4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(+35.3%)</td>
<td>4,557.0</td>
<td>3,497.1</td>
<td>+1,059.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(+30.3%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>营业利润</td>
<td>528.3</td>
<td>314.7</td>
<td>+213.6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(67.9%)</td>
<td>2,069.2</td>
<td>1,321.4</td>
<td>+747.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(+56.6%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EBITDA</td>
<td>623.5</td>
<td>388.7</td>
<td>+234.8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(+60.4%)</td>
<td>2,439.1</td>
<td>1,622.2</td>
<td>+816.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(+50.4%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div><p><strong>Business Updates and 2026 Outlook</strong></p>
<div class="lb-trans"><p><strong>业务更新及 2026 年展望</strong></p>
</div><p>Samsung Biologics continued to expand its global CDMO business through long-term partnerships with pharmaceutical companies worldwide. The company secured a KRW 1.1 trillion manufacturing agreement with a European pharmaceutical company in the fourth quarter of 2025, contributing to a cumulative contract value exceeding USD 21 billion. Cumulative regulatory approvals reached 420, reflecting the company's continued focus on quality, compliance, and consistent regulatory execution across global markets.</p>
<div class="lb-trans"><p>三星生物制剂通过与全球制药公司建立长期合作关系，继续扩展其全球 CDMO 业务。公司在 2025 年第四季度与一家欧洲制药公司签署了价值 1.1 万亿韩元的制造协议，使累计合同价值超过 210 亿美元。累计监管批准达到 420 项，反映出公司持续关注质量、合规性和在全球市场上的一致监管执行。</p>
</div><p>The company reaffirmed its strategic direction as a pure-play CDMO through an equity spin-off, and continued to advance initiatives to strengthen its global manufacturing platform. Operations across Plants 1 through 4 remained stable, providing a solid operational base, while Plant 5 will begin contributing to revenue in 2026. Based on this outlook, excluding potential contributions from the planned acquisition of the U.S. site, the company projected 15–20% annual revenue growth for 2026.</p>
<div class="lb-trans"><p>公司通过股权剥离重申了其作为纯粹 CDMO 的战略方向，并继续推进加强其全球制造平台的举措。第一至第四工厂的运营保持稳定，提供了坚实的运营基础，而第五工厂将在 2026 年开始贡献收入。基于这一展望，排除计划收购美国工厂的潜在贡献，公司预计 2026 年年收入增长 15-20%。</p>
</div><p>Samsung Biologics progressed key infrastructure and capacity investments to support future demand. In December 2025, the company announced the planned acquisition of a U.S. manufacturing facility in Rockville, Maryland, to further support supply resilience and proximity to clients. The site comprises two CGMP manufacturing plants with a combined 60 kL of drug substance capacity, supporting mid- to large-scale programs. The deal is expected to close in the first quarter of 2026, and the company intends to make additional investments to increase capacity and upgrade technology at the site.</p>
<div class="lb-trans"><p>三星生物制剂推进了关键基础设施和产能投资，以支持未来需求。2025 年 12 月，公司宣布计划收购位于马里兰州罗克维尔的美国制造设施，以进一步支持供应韧性和靠近客户。该地点包括两个 CGMP 制造工厂，合计 60 kL 的药物物质产能，支持中到大规模项目。交易预计将在 2026 年第一季度完成，公司计划进行额外投资以增加产能和升级该地点的技术。</p>
</div><p>The company also secured land for Bio Campus III, establishing a foundation for future expansion to support next-generation modalities and diversified client needs. Bio Campus III is expected to support expanded capabilities across advanced conjugation technologies, as well as cell and gene therapies and antibody vaccines.</p>
<div class="lb-trans"><p>公司还为生物园区 III 获得了土地，为未来扩展奠定基础，以支持下一代技术和多样化的客户需求。生物园区 III 预计将支持在先进的结合技术、细胞和基因疗法以及抗体疫苗方面的扩展能力。</p>
</div><p>Under its optimized manufacturing framework, ExellenS™, Samsung Biologics continued to invest in operational systems, digital capabilities, and manufacturing infrastructure to enhance readiness and execution across its facilities. The company is expanding its drug product capabilities, including preparations for a fully automated pre-filled syringe drug product line, which is expected to be CGMP ready by 2027.</p>
<div class="lb-trans"><p>在其优化的制造框架 ExellenS™下，三星生物制剂继续投资于运营系统、数字能力和制造基础设施，以增强其设施的准备和执行能力。公司正在扩展其药物产品能力，包括为完全自动化的预填充注射器药物产品线做准备，预计将在 2027 年达到 CGMP 标准。</p>
</div><p>Samsung Biologics continued to advance its environmental, social, and governance (ESG) initiatives. The company received an 'A' rating in Water Security from the Carbon Disclosure Project (CDP) and continued its role as a Champion of the Sustainable Markets Initiative, supporting collaborative action toward more sustainable healthcare manufacturing practices. By strengthening engagement with suppliers and integrating ESG considerations across its operations and value chain, Samsung Biologics aims to support long-term environmental stewardship while maintaining reliable and responsible manufacturing operations.</p>
<div class="lb-trans"><p>三星生物制剂继续推进其环境、社会和治理（ESG）倡议。公司在碳披露项目（CDP）中获得了水安全 “A” 评级，并继续作为可持续市场倡议的冠军，支持朝着更可持续的医疗制造实践的协作行动。通过加强与供应商的互动，并在其运营和价值链中整合 ESG 考量，三星生物制剂旨在支持长期的环境管理，同时保持可靠和负责任的制造运营。</p>
</div><p>For more details on performance and financials, please refer to the Earnings Release.</p>
<div class="lb-trans"><p>有关业绩和财务的更多详细信息，请参阅财报。</p>
</div><p><strong>About Samsung Biologics Co., Ltd</strong>.</p>
<div class="lb-trans"><p><strong>关于三星生物制剂有限公司</strong></p>
</div><p>Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.</p>
<div class="lb-trans"><p>三星生物制剂（KRX: 207940.KS）是一家领先的合同开发和制造组织（CDMO），提供从后期发现到商业制造的端到端综合服务。</p>
</div><p>With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II, and 60,000 from the planned acquisition of a manufacturing facility in Rockville, Maryland, U.S. upon deal closure at the end of Q1 2026, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.</p>
<div class="lb-trans"><p>三星生物制剂在生物园区 I 和 II 的合计生物制造能力为 785,000 升，并计划在 2026 年第一季度末完成对美国马里兰州罗克维尔一家制造设施的收购，增加 60,000 升的产能。三星生物制剂利用尖端技术和专业知识推进多种治疗方式，包括多特异性抗体、融合蛋白、抗体药物偶联物和 mRNA 治疗。</p>
</div><p>By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity.</p>
<div class="lb-trans"><p>通过在其制造网络中实施 ExellenS™框架，采用标准化设计、统一流程和先进数字化，三星生物制剂确保工厂的等效性和制造连续性的速度。</p>
</div><p>Samsung Biologics' global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health.</p>
<div class="lb-trans"><p>三星生物制剂的全球制造和商业网络覆盖韩国、美国和日本。三星生物制剂美国公司支持位于美国和欧洲的客户，而其东京销售办公室服务于亚太地区。三星生物制剂持续投资于新能力，以最大化运营和质量卓越，确保客户的灵活性和敏捷性。公司致力于按时、完整地交付安全、高质量的生物药品，并做出可持续的商业决策，以改善社会和全球健康。</p>
</div><p>For more information, visit https://samsungbiologics.com/.</p>
<div class="lb-trans"><p>欲了解更多信息，请访问 https://samsungbiologics.com/。</p>
</div><p><strong>Media Contact</strong> Claire Kim, Senior Director [email protected]</p>
<div class="lb-trans"><p><strong>媒体联系人</strong> Claire Kim, 高级总监 [email protected]</p>
</div><p>Becky Lee, Director [email protected]</p>
<div class="lb-trans"><p>Becky Lee, 总监 [email protected]</p>
</div><p>SOURCE Samsung Biologics</p>
<div class="lb-trans"><p>来源 三星生物制剂</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTIxJk5ld3NJdGVtSWQ9Q042Nzc1OSZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjEwMjIwUFJfTkVXU19VU1BSX19fX19DTjY3NzU5" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CN67759&amp;Transmission_Id=202601210220PR_NEWS_USPR_____CN67759&amp;DateId=20260121"/></p>

三星生物制剂发布 2025 财年第四季度及全年财务报告